Myeloproliferative neoplasms: Current molecular biology and genetics

Critical Reviews in Oncology/Hematology

Volumn 98, Issue , 2016, Pages 375-389

  Saeidi, Kolsoum ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CALR; JAK2; Myeloproliferative neoplasms; Polycythemia vera

Indexed keywords

ASXL1 PROTEIN; CALRETICULIN; CBL PROTEIN; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; HIGH MOBILITY GROUP A2 PROTEIN; IKAROS FAMILY ZINC FINGER PROTEIN 1; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; K RAS PROTEIN; PROTEIN P53; SH2B3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TET2 PROTEIN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; CALRETICULIN, HUMAN; CBL PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; EZH2 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN;

ASXL1 GENE; CALR GENE; CBL GENE; DNMT3A GENE; EXON; EZH2 GENE; FLT3 GENE; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HMGA2 GENE; HUMAN; IDH1 GENE; IDH2 GENE; IKZF1 GENE; JAK2 GENE; KRAS GENE; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MPL GENE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; NRAS GENE; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; PROTO ONCOGENE; REVIEW; SH2B3 GENE; SOCS GENE; SOMATIC MUTATION; TET2 GENE; THROMBOCYTHEMIA; TP53 GENE; GENETICS; MUTATION; TUMOR SUPPRESSOR GENE;

CALRETICULIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EXONS; GENES, P53; HUMANS; JANUS KINASE 2; MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84957428955     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.11.004     Document Type: Review

References (232)

1. Abbas S., Rotmans G., Lowenberg B., Valk P.J. Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica 2008, 93:1595-1597.
2. Abbas S., Lugthart S., Kavelaars F.G., Schelen A., Koenders J.E., Zeilemaker A., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010, 116:2122-2126.
3. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
4. Abdel-Wahab O., Manshouri T., Patel J., Harris K., Yao J., Hedvat C., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010, 70:447-452.
5. Abdel-Wahab O., Pardanani A., Rampal R., Lasho T.L., Levine R.L., Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011, 25:1219-1220.
6. Abdel-Wahab O., Adli M., LaFave L.M., Gao J., Hricik T., Shih A.H., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012, 22:180-193.
7. Abe M., Suzuki K., Inagaki O., Sassa S., Shikama H. A novel MPL point mutation resulting in thrombopoietin-independent activation. Leukemia 2002, 16:1500-1506.
8. Akpinar T.S., Hancer V.S., Nalcaci M., Diz-Kucukkaya R. MPL W515L/K Mutations in chronic myeloproliferative neoplasms. Turk. J. Haematol. 2013, 30:8-12.
9. Aliano S., Cirmena G., Garuti A., Fugazza G., Bruzzone R., Rocco I., et al. HMGA2 overexpression in polycythemia vera with t(12;21)(q14;q22). Cancer Genet. Cytogenet. 2007, 177:115-119.
10. Bains A., Luthra R., Medeiros L.J., Zuo Z. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am. J. Clin. Pathol. 2011, 135:62-69.
11. Barbui T., Carobbio A., Rambaldi A., Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. Blood 2009, 114:759-763.
12. Barbui T., Barosi G., Birgegard G., Cervantes F., Finazzi G., Griesshammer M., et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J. Clin. Oncol. 2011, 29:761-770.
13. Barbui T., Finazzi G., Carobbio A., Thiele J., Passamonti F., Rumi E., et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012, 120:5128-5133. quiz 252.
14. Barosi G., Bergamaschi G., Marchetti M., Vannucchi A.M., Guglielmelli P., Antonioli E., et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007, 110:4030-4036.
15. Barosi G. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. Best Pract. Res. Clin. Haematol. 2014, 27:129-140.
16. Barrio S., Gallardo M., Albizua E., Jimenez A., Rapado I., Ayala R., et al. Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. J. Clin. Pathol. 2011, 64:1010-1013.
17. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
18. Beer P.A., Campbell P.J., Scott L.M., Bench A.J., Erber W.N., Bareford D., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008, 112:141-149.
19. Beer P.A., Delhommeau F., LeCouedic J.P., Dawson M.A., Chen E., Bareford D., et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010, 115:2891-2900.
20. Beer P.A., Ortmann C.A., Stegelmann F., Guglielmelli P., Reilly J.T., Larsen T.S., et al. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica 2010, 95:2153-2156.
21. Benekli M., Baer M.R., Baumann H., Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101:2940-2954.
22. Bersenev A., Wu C., Balcerek J., Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J. Clin. Invest. 2008, 118:2832-2844.
23. Boyd E.M., Bench A.J., Goday-Fernandez A., Anand S., Vaghela K.J., Beer P., et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br. J. Haematol. 2010, 149:250-257.
24. Brecqueville M., Cervera N., Gelsi-Boyer V., Murati A., Adelaide J., Chaffanet M., et al. Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer J. 2011, 1:e18.
25. Brecqueville M., Rey J., Bertucci F., Coppin E., Finetti P., Carbuccia N., et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012, 51:743-755.
26. Broseus J., Park J.H., Carillo S., Hermouet S., Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014, 124:3964-3966.
27. Butcher C.M., Hahn U., To L.B., Gecz J., Wilkins E.J., Scott H.S., et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2008, 22:870-873.
28. Caligiuri M.A., Briesewitz R., Yu J., Wang L., Wei M., Arnoczky K.J., et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 2007, 110:1022-1024.
29. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366:1945-1953.
30. Campbell P.J., Griesshammer M., Dohner K., Dohner H., Kusec R., Hasselbalch H.C., et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006, 107:2098-2100.
31. Campregher P.V., Santos F.P., Perini G.F., Hamerschlak N. Molecular biology of Philadelphia-negative myeloproliferative neoplasms. Rev. Bras. Hematol. Hemoterapia 2012, 34:150-155.
32. Capello D., Deambrogi C., Rossi D., Lischetti T., Piranda D., Cerri M., et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br. J. Haematol. 2008, 141:504-511.
33. Carbuccia N., Murati A., Trouplin V., Brecqueville M., Adelaide J., Rey J., et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009, 23:2183-2186.
34. Carbuccia N., Trouplin V., Gelsi-Boyer V., Murati A., Rocquain J., Adelaide J., et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010, 24:469-473.
35. Carobbio A., Finazzi G., Guerini V., Spinelli O., Delaini F., Marchioli R., et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007, 109:2310-2313.
36. Carobbio A., Antonioli E., Guglielmelli P., Vannucchi A.M., Delaini F., Guerini V., et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J. Clin. Oncol. 2008, 26:2732-2736.
37. Cazzola M., Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014, 123:3714-3719.
38. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
39. Chaligne R., Tonetti C., Besancenot R., Roy L., Marty C., Mossuz P., et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008, 22:1557-1566.
40. Chotirat S., Thongnoppakhun W., Wanachiwanawin W., Auewarakul C.U. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders. Blood Cells Mol. Dis. 2014.
41. Chou F.S., Mulloy J.C. The thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis. J. Cell. Biochem. 2011, 112:1491-1498.
42. Conchon M. The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia. Rev. Bras. Hematol. Hemoterapia 2011, 33:401-402.
43. Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol. Med. 2010, 16:387-397.
44. Delhommeau F., Dupont S., Della V., alle V., James C., Trannoy S., Masse A., et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009, 360:2289-2301.
45. Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004, 103:4198-4200.
46. Ding Y., Harada Y., Imagawa J., Kimura A., Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 2009, 114:5201-5205.
47. Dos Santos L.C., Ribeiro J.C., Silva N.P., Cerutti J., da Silva M.R., de Chauffaille M.L. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia. Rev. Bras. Hematol. Hemoterapia 2011, 33:417-424.
48. Dunbar A.J., Gondek L.P., O'Keefe C.L., Makishima H., Rataul M.S., Szpurka H., et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008, 68:10349-10357.
49. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42:722-726.
50. Etienne A., Carbuccia N., Adelaide J., Bekhouche I., Remy V., Sohn C., et al. Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet. Cytogenet. 2007, 176:80-88.
51. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
52. Finazzi G., Rambaldi A., Guerini V., Carobbo A., Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007, 92:135-136.
53. Firmbach-Kraft I., Byers M., Shows T., Dalla-Favera R., Krolewski J.J. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 1990, 5:1329-1336.
54. Fourouclas N., Li J., Gilby D.C., Campbell P.J., Beer P.A., Boyd E.M., et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 2008, 93:1635-1644.
55. Fu J.F., Hsu J.J., Tang T.C., Shih L.Y. Identification of CBL, a proto-oncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosomes Cancer 2003, 37:214-219.
56. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007, 7:899-910.
57. Gangat N., Wolanskyj A.P., McClure R.F., Li C.Y., Schwager S., Wu W., et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007, 21:270-276.
58. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 2011, 29:392-397.
59. Gelsi-Boyer V., Trouplin V., Adelaide J., Bonansea J., Cervera N., Carbuccia N., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 2009, 145:788-800.
60. Gelsi-Boyer V., Brecqueville M., Devillier R., Murati A., Mozziconacci M.J., Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J. Hematol. Oncol. 2012, 5:12.
61. Georgiou G., Karali V., Zouvelou C., Kyriakou E., Dimou M., Chrisochoou S., et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br. J. Haematol. 2006, 134:302-306.
62. Georgopoulos K. Haematopoietic cell-fate decisions chromatin regulation and ikaros. Nat. Rev. Immunol. 2002, 2:162-174.
63. Gery S., Cao Q., Gueller S., Xing H., Tefferi A., Koeffler H.P. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J. Leukoc. Biol. 2009, 85:957-965.
64. Ghoreschi K., Laurence A., O'Shea J.J. Janus kinases in immune cell signaling. Immunol. Rev. 2009, 228:273-287.
65. Grand F.H., Hidalgo-Curtis C.E., Ernst T., Zoi K., Zoi C., McGuire C., et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009, 113:6182-6192.
66. Guglielmelli P., Pancrazzi A., Bergamaschi G., Rosti V., Villani L., Antonioli E., et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br. J. Haematol. 2007, 137:244-247.
67. Guglielmelli P., Biamonte F., Score J., Hidalgo-Curtis C., Cervantes F., Maffioli M., et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011, 118:5227-5234.
68. Gurney A.L., Wong S.C., Henzel W.J., de Sauvage F.J. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5292-5296.
69. Ha J.S., Jeon D.S., Kim J.R., Ryoo N.H., Suh J.S. Analysis of the ten-eleven translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. Ann. Clin. Lab. Sci. 2014, 44:173-179.
70. Harada H., Harada Y., Niimi H., Kyo T., Kimura A., Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004, 103:2316-2324.
71. Harada-Shirado K., Ikeda K., Ogawa K., Ohkawara H., Kimura H., Kai T., et al. Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. Br. J. Haematol. 2014.
72. Harutyunyan A., Klampfl T., Cazzola M., Kralovics R. p53 lesions in leukemic transformation. N. Engl. J. Med. 2011, 364:488-490.
73. Hasan S. JAK2V617F-positive myeloproliferative neoplasms: KI mouse models. Interferon- A Therapy and Clonal Architecture 2013, Universite Paris Sud, Paris, XI; 2013.
74. Haslam K., Langabeer S.E. Incidence of CALR mutations in patients with splanchnic vein thrombosis. Br. J. Haematol. 2014.
75. Hussein K., Bock O., Theophile K., Schulz-Bischof K., Porwit A., Schlue J., et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009, 23:852-855.
76. Hussein K., Van Dyke D.L., Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur. J. Haematol. 2009, 82:329-338.
77. Ikeda K., Mason P.J., Bessler M. 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood 2011, 117:5860-5869.
78. Ikeda K., Ogawa K., Takeishi Y. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms. Fukushima J. Med. Sci. 2012, 58:91-100.
79. Im A.P., Sehgal A.R., Carroll M.P., Smith B.D., Tefferi A., Johnson D.E., et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014, 28:1774-1783.
80. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
81. Jager R., Kralovics R. Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms. Curr. Cancer Drug Targets 2011, 11:20-30.
82. Jager R., Gisslinger H., Passamonti F., Rumi E., Berg T., Gisslinger B., et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 2010, 24:1290-1298.
83. James C., Ugo V., Le C., ouedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
84. Jamieson C.H., Gotlib J., Durocher J.A., Chao M.P., Mariappan M.R., Lay M., et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6224-6229.
85. Jankowska A.M., Szpurka H., Tiu R.V., Makishima H., Afable M., Huh J., et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113:6403-6410.
86. Jankowska A.M., Makishima H., Tiu R.V., Szpurka H., Huang Y., Traina F., et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011, 118:3932-3941.
87. Jelinek J., Oki Y., Gharibyan V., Bueso-Ramos C., Prchal J.T., Verstovsek S., et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 106:3370-3373.
88. Johan M.F., Goodeve A.C., Bowen D.T., Frew M.E., Reilly J.T. JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia. Br. J. Haematol. 2005, 130:968.
89. Jones A.V., Chase A., Silver R.T., Oscier D., Zoi K., Wang Y.L., et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 2009, 41:446-449.
90. Jost E., do O.N., Dahl E., Maintz C.E., Jousten P., Habets L., et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 2007, 21:505-510.
91. Kastner P., Chan S. Role of Ikaros in T-cell acute lymphoblastic leukemia. World J. Biol. Chem. 2011, 2:108-114.
92. Katoh M. Functional and cancer genomics of ASXL family members. Br. J. Cancer 2013, 109:299-306.
93. Kilpivaara O., Mukherjee S., Schram A.M., Wadleigh M., Mullally A., Ebert B.L., et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat. Genet. 2009, 41:455-459.
94. Kittur J., Knudson R.A., Lasho T.L., Finke C.M., Gangat N., Wolanskyj A.P., et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007, 109:2279-2284.
95. Klampfl T., Harutyunyan A., Berg T., Gisslinger B., Schalling M., Bagienski K., et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011, 118:167-176.
96. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 2013, 369:2379-2390.
97. Kosmider O., Gelsi-Boyer V., Cheok M., Grabar S., Della-Valle V., Picard F., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114:3285-3291.
98. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
99. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108:1652-1660.
100. Lambert M.P., Jiang J., Batra V., Wu C., Tong W. A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia. Am. J. Hematol. 2012, 87:532-534.
101. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009, 41:838-842.
102. Lasho T.L., Pardanani A., McClure R.F., Mesa R.A., Levine R.L., Gilliland D.G., et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br. J. Haematol. 2006, 135:683-687.
103. Lasho T.L., Pardanani A., Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N. Engl. J. Med. 2010, 363:1189-1190.
104. Lavi N. Calreticulin mutations in myeloproliferative neoplasms. Rambam Maimonides Med. J. 2014, 5:e0035.
105. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
106. Levine R.L., Loriaux M., Huntly B.J., Loh M.L., Beran M., Stoffregen E., et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005, 106:3377-3379.
107. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 2010, 363:2424-2433.
108. Li O., Li J., Droge P. DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells. FEBS Lett. 2007, 581:3533-3537.
109. Li J., Kent D.G., Chen E., Green A.R. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis. Models Mech. 2011, 4:311-317.
110. Liu K.D., Gaffen S.L., Goldsmith M.A. JAK/STAT signaling by cytokine receptors. Curr. Opin. Immunol. 1998, 10:271-278.
111. Loh M.L., Sakai D.S., Flotho C., Kang M., Fliegauf M., Archambeault S., et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009, 114:1859-1863.
112. Lu M., Hoffman R. p5 as a target in myeloproliferative neoplasms. Oncotarget 2012, 3:1052-1053.
113. Lundberg P., Karow A., Nienhold R., Looser R., Hao-Shen H., Nissen I., et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014, 123:2220-2228.
114. Luo B., Lee A.S. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 2013, 32:805-818.
115. Luo H., Rose P., Barber D., Hanratty W.P., Lee S., Roberts T.M., et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell. Biol. 1997, 17:1562-1571.
116. Lussana F., Caberlon S., Pagani C., Kamphuisen P.W., Buller H.R., Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb. Res. 2009, 124:409-417.
117. Makishima H., Cazzolli H., Szpurka H., Dunbar A., Tiu R., Huh J., et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol. 2009, 27:6109-6116.
118. Makishima H., Jankowska A.M., Tiu R.V., Szpurka H., Sugimoto Y., Hu Z., et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010, 24:1799-1804.
119. Martinez-Aviles L., Besses C., Alvarez-Larran A., Cervantes F., Hernandez-Boluda J.C., Bellosillo B. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. Haematologica 2007, 92:1717-1718.
120. Martinez-Aviles L., Besses C., Alvarez-Larran A., Torres E., Serrano S., Bellosillo B. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Ann. Hematol. 2012, 91:533-541.
121. McGaffin G., Harper K., Stirling D., McLintock L. JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br. J. Haematol. 2014, 167:276-278.
122. Mesa R.A., Powell H., Lasho T., Dewald G., McClure R., Tefferi A. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leukemia Res. 2006, 30:1457-1460.
123. Michalak M., Corbett E.F., Mesaeli N., Nakamura K., Opas M. Calreticulin one protein, one gene, many functions. Biochem. J. 1999, 344(Pt 2):281-292.
124. Michalak M., Groenendyk J., Szabo E., Gold L.I., Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem. J. 2009, 417:651-666.
125. Mohamedali A.M., Smith A.E., Gaken J., Lea N.C., Mian S.A., Westwood N.B., et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J. Clin. Oncol. 2009, 27:4002-4006.
126. Moliterno A.R., Williams D.M., Gutierrez-Alamillo L.I., Salvatori R., Ingersoll R.G., Spivak J.L. Mpl Baltimore a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11444-11447.
127. Mullighan C., Downing J. Ikaros and acute leukemia. Leukemia Lymphoma 2008, 49:847-849.
128. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 2013, 369:2391-2405.
129. Nikoloski G., Langemeijer S.M., Kuiper R.P., Knops R., Massop M., Tonnissen E.R., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42:665-667.
130. Nussenzveig R.H., Swierczek S.I., Jelinek J., Gaikwad A., Liu E., Verstovsek S., et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp. Hematol. 2007, 35:32-38.
131. Ogawa S., Sanada M., Shih L.Y., Suzuki T., Otsu M., Nakauchi H., et al. Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms. Cell Cycle 2010, 9:1051-1056.
132. Oh S.T., Simonds E.F., Jones C., Hale M.B., Goltsev Y., Gibbs K.D., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116:988-992.
133. Ortmann C.A., Kent D.G., Nangalia J., Silber Y., Wedge D.C., Grinfeld J., et al. Effect of mutation order on myeloproliferative neoplasms. N. Engl. J. Med. 2015, 372:601-612.
134. Ozeki K., Kiyoi H., Hirose Y., Iwai M., Ninomiya M., Kodera Y., et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004, 103:1901-1908.
135. Pagliarini-e-Silva S., Santos B.C., Pereira E.M., Ferreira M.E., Baraldi E.C., Sell A.M., et al. Evaluation of the association between the JAK2 46/1 haplotype and chronic myeloproliferative neoplasms in a Brazilian population. Clinics 2013, 68:5-9.
136. Pancrazzi A., Guglielmelli P., Ponziani V., Bergamaschi G., Bosi A., Barosi G., et al. A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J. Mol. Diagn. 2008, 10:435-441.
137. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
138. Pardanani A., Lasho T.L., Finke C., Hanson C.A., Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007, 21:1960-1963.
139. Pardanani A., Fridley B.L., Lasho T.L., Gilliland D.G., Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008, 111:2785-2789.
140. Pardanani A., Lasho T.L., Finke C.M., Mai M., McClure R.F., Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010, 24:1146-1151.
141. Pardanani A., Lasho T., Finke C., Oh S.T., Gotlib J., Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010, 24:1713-1718.
142. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Pereira A., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
143. Passamonti F., Elena C., Schnittger S., Skoda R.C., Green A.R., Girodon F., et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011, 117:2813-2816.
144. Passamonti F., Thiele J., Girodon F., Rumi E., Carobbio A., Gisslinger H., et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012, 120:1197-1201.
145. Patriarca A., Colaizzo D., Tiscia G., Spadano R., Di Z., Acomo S., Spadano A., et al. TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings. BioMed Res. Int. 2013, 2013:929840.
146. Paulsson K., Haferlach C., Fonatsch C., Hagemeijer A., Andersen M.K., Slovak M.L., et al. The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. Hum. Mol. Genet. 2010, 19:1507-1514.
147. Percy M.J., Scott L.M., Erber W.N., Harrison C.N., Reilly J.T., Jones F.G., et al. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 2007, 92:1607-1614.
148. Pich A., Riera L., Sismondi F., Godio L., Davico B., onino L., Marmont F., et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J. Clin. Pathol. 2009, 62:798-801.
149. Pietra D., Li S., Brisci A., Passamonti F., Rumi E., Theocharides A., et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008, 111:1686-1689.
150. Pietra D., Brisci A., Rumi E., Boggi S., Elena C., Pietrelli A., et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica 2011, 96:607-611.
151. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3:e270.
152. Pocanschi C.L., Kozlov G., Brockmeier U., Brockmeier A., Williams D.B., Gehring K. Structural and functional relationships between the lectin and arm domains of calreticulin. J. Biol. Chem. 2011, 286:27266-27277.
153. Pritchard M.A., Baker E., Callen D.F., Sutherland G.R., Wilks A.F. Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24. Mamm. Genome 1992, 3:36-38.
154. Qin Y.W., Yang Y.N., Li S., Wang C. Coexistence of JAK2V617F mutation and BCR-ABL Translocation in a pregnant woman with essential thrombocythemia. Indian J. Hematol. Blood Transfus. 2014, 30:331-334.
155. Rane S.G., Reddy E.P. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994, 9:2415-2423.
156. Rathinam C., Thien C.B., Flavell R.A., Langdon W.Y. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. Cancer Cell 2010, 18:341-352.
157. Raza S., Viswanatha D., Frederick L., Lasho T., Finke C., Knudson R., et al. TP53 mutations and polymorphisms in primary myelofibrosis. Am. J. Hematol. 2012, 87:204-206.
158. Reindl C., Bagrintseva K., Vempati S., Schnittger S., Ellwart J.W., Wenig K., et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 2006, 107:3700-3707.
159. Remacha A.F., Nomdedeu J.F., Puget G., Estivill C., Sarda M.P., Canals C., et al. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2006, 91:719-720.
160. Renneville A., Quesnel B., Charpentier A., Terriou L., Crinquette A., Lai J.L., et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006, 20:2067-2070.
161. Riedy M.C., Dutra A.S., Blake T.B., Modi W., Lal B.K., Davis J., et al. Genomic sequence, organization, and chromosomal localization of human JAK3. Genomics 1996, 37:57-61.
162. Rotunno G., Mannarelli C., Guglielmelli P., Pacilli A., Pancrazzi A., Pieri L., et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014, 123:1552-1555.
163. Rudd C.E. Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci. STKE 2001, 2001:pe 1.
164. Rumi E., Harutyunyan A.S., Pietra D., Milosevic J.D., Casetti I.C., Bellini M., et al. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood 2014, 123:2416-2419.
165. Saharinen P., Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 2002, 277:47954-47963.
166. Saint-Martin C., Leroy G., Delhommeau F., Panelatti G., Dupont S., James C., et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009, 114:1628-1632.
167. Sanada M., Suzuki T., Shih L.Y., Otsu M., Kato M., Yamazaki S., et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460:904-908.
168. Sangkhae V., Etheridge S.L., Kaushansky K., Hitchcock I.S. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood 2014, 124:3956-3963.
169. Sattler M., Durstin M.A., Frank D.A., Okuda K., Kaushansky K., Salgia R., et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp. Hematol. 1995, 23:1040-1048.
170. Schaub F.X., Looser R., Li S., Hao-Shen H., Lehmann T., Tichelli A., et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010, 115:2003-2007.
171. Schnittger S., Bacher U., Haferlach C., Beelen D., Bojko P., Burkle D., et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 2009, 94:141-144.
172. Schnittger S., Bacher U., Alpermann T., Reiter A., Ulke M., Dicker F., et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. Haematologica 2012, 97:1890-1894.
173. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 2007, 356:459-468.
174. Shen H., Chao H., Ding Z., Feng Y., Cen J., Pan J., et al. CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia. Leukemia Lymphoma 2015, 56:820-822.
175. Shide K., Kameda T., Shimoda H., Yamaji T., Abe H., Kamiunten A., et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 2012, 26:2216-2223.
176. Shih L.Y., Lin T.L., Wang P.N., Wu J.H., Dunn P., Kuo M.C., et al. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer 2004, 101:989-998.
177. Shirane S., Araki M., Morishita S., Edahiro Y., Takei H., Yoo Y., et al. JAK2, CALR, and MPL mutation spectrum in Japanese myeloproliferative neoplasms patients. Haematologica 2014.
178. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 2008, 647:21-29.
179. Small D. FLT3 mutations: biology and treatment. Hematology/the Education Program of the American Society of Hematology 2006, 178-184. American Society of Hematology Education Program.
180. Soriano G., Heaney M. Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications. Curr. Opin. Hematol. 2013, 20:169-175.
181. Staerk J., Lacout C., Sato T., Smith S.O., Vainchenker W., Constantinescu S.N. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood 2006, 107:1864-1871.
182. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106:1207-1209.
183. Steensma D.P., McClure R.F., Karp J.E., Tefferi A., Lasho T.L., Powell H.L., et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006, 20:971-978.
184. Storlazzi C.T., Albano F., Locunsolo C., Lonoce A., Funes S., Guastadisegni M.C., et al. t(3;12)(q26;q14) in polycythemia vera is associated with upregulation of the HMGA2 gene. Leukemia 2006, 20:2190-2192.
185. Sun C., Zhang S., Li J. Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations. Leukemia Lymphoma 2014, 1-6.
186. Swaminathan G., Tsygankov A.Y. The Cbl family proteins: ring leaders in regulation of cell signaling. J. Cell. Physiol. 2006, 209:21-43.
187. Swierczek S.I., Yoon D., Bellanne-Chantelot C., Kim S.J., Saint-Martin C., Delhommeau F., et al. Extent of hematopoietic involvement by TET2 mutations in JAK2V(6)(1)(7)F polycythemia vera. Haematologica 2011, 96:775-778.
188. Szpurka H., Tiu R., Murugesan G., Aboudola S., Hsi E.D., Theil K.S., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006, 108:2173-2181.
189. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
190. Takaki S., Morita H., Tezuka Y., Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J. Exp. Med. 2002, 195:151-160.
191. Taksin A.L., Couedic J.P., Dusanter-Fourt I., Masse A., Giraudier S., Katz A., et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 1999, 93:125-139.
192. Tefferi A., Pardanani A. Myeloproliferative neoplasms-a contemporary review. JAMA Oncol. 2015, 1:97-105.
193. Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., Barbui T., Hanson C.A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
194. Tefferi A., Thiele J., Vardiman J.W. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009, 115:3842-3847.
195. Tefferi A., Levine R.L., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23:900-904.
196. Tefferi A., Pardanani A., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23:905-911.
197. Tefferi A., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., Patnaik M.M., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23:1343-1345.
198. Tefferi A., Guglielmelli P., Lasho T.L., Rotunno G., Finke C., Mannarelli C., et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014, 28:1494-1500.
199. Tefferi A., Wassie E.A., Lasho T.L., Finke C., Belachew A.A., Ketterling R.P., et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014, 28:2300-2303.
200. Tefferi A., Lasho T.L., Finke C., Belachew A.A., Wassie E.A., Ketterling R.P., et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 2014, 28:1568-1570.
201. Tefferi A., Lasho T.L., Finke C.M., Knudson R.A., Ketterling R., Hanson C.H., et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014, 28:1472-1477.
202. Tefferi A., Thiele J., Vannucchi A.M., Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014, 28:1407-1413.
203. Tefferi A., Lasho T.L., Tischer A., Wassie E.A., Finke C.M., Belachew A.A., et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014, 124:2465-2466.
204. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
205. Tefferi A. How I treat myelofibrosis. Blood 2011, 117:3494-3504.
206. Teofili L., Martini M., Cenci T., Guidi F., Torti L., Giona F., et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int. J. Cancer 2008, 123:1586-1592.
207. Teofili L., Giona F., Torti L., Cenci T., Ricerca B.M., Rumi C., et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 2010, 95:65-70.
208. Them N.C., Kralovics R. Genetic basis of MPN: beyond JAK2-V617F. Curr. Hematol. Malig. Rep. 2013, 8:299-306.
209. Theocharides A., Boissinot M., Girodon F., Garand R., Teo S.S., Lippert E., et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007, 110:375-379.
210. Tong W., Lodish H.F. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J. Exp. Med. 2004, 200:569-580.
211. Turon F., Cervantes F., Colomer D., Baiges A., Hernandez-Gea V., Garcia-Pagan J.C. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. J. Hepatol. 2015, 62:72-74.
212. Vainchenker W., Delhommeau F., Constantinescu S.N., Bernard O.A. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011, 118:1723-1735.
213. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110:840-846.
214. Vannucchi A.M., Antonioli E., Guglielmelli P., Pancrazzi A., Guerini V., Barosi G., et al. Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia. Blood 2008, 112:844-847.
215. Vannucchi A.M., Lasho T.L., Guglielmelli P., Biamonte F., Pardanani A., Pereira A., et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, 27:1861-1869.
216. Vannucchi A.M. Management of myelofibrosis. Hematology/the Education Program of the American Society of Hematology 2011, 222-230. American Society of Hematology Education Program, 2011.
217. Velazquez L., Cheng A.M., Fleming H.E., Furlonger C., Vesely S., Bernstein A., et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J. Exp. Med. 2002, 195:1599-1611.
218. Verstovsek S., Silver R.T., Cross N.C., Tefferi A. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?. Leukemia 2006, 20:2067.
219. Vizmanos J.L., Ormazabal C., Larrayoz M.J., Cross N.C., Calasanz M.J. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia 2006, 20:534-535.
220. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25:1153-1158.
221. Wang S.A., Hasserjian R.P., Loew J.M., Sechman E.V., Jones D., Hao S., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 2006, 20:1641-1644.
222. Wang W.A., Groenendyk J., Michalak M. Calreticulin signaling in health and disease. Int. J. Biochem. Cell Biol. 2012, 44:842-846.
223. Wang M., He N., Tian T., Liu L., Yu S., Ma D. Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms. BioMed Res. Int. 2014, 2014:485645.
224. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107:4274-4281.
225. Williams D.M., Kim A.H., Rogers O., Spivak J.L., Moliterno A.R. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp. Hematol. 2007, 35:1641-1646.
226. Williams L., Kelley H.H., Meng X., Prada A., Crisan D. FLT3 mutations in myeloproliferative neoplasms: the Beaumont experience. Diagn. Mol. Pathol. 2013, 22:156-160.
227. Xia J., Lu M.Z., Jiang Y.Q., Yang G.H., Zhuang Y., Sun H.L., et al. JAK2 V617F, MPL W515L and JAK2 exon 12 mutations in chinese patients with primary myelofibrosis. Chin. J. Cancer Res. 2012, 24:72-76.
228. Yamashita Y., Yuan J., Suetake I., Suzuki H., Ishikawa Y., Choi Y.L., et al. Array-based genomic resequencing of human leukemia. Oncogene 2010, 29:3723-3731.
229. Yan X.J., Xu J., Gu Z.H., Pan C.M., Lu G., Shen Y., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 2011, 43:309-315.
230. Young A.R., Narita M. Oncogenic HMGA2: short or small?. Genes Dev. 2007, 21:1005-1009.
231. Zhang S.J., Rampal R., Manshouri T., Patel J., Mensah N., Kayserian A., et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012, 119:4480-4485.
232. Zhang M.Y., Fung T.K., Chen F.Y., Chim C.S. Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm. J. Cell. Mol. Med. 2013, 17:1282-1290.